Journals / Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi / 2022 / Cilt: 19 - Sayı: 3

Can prokineticin 1 be used as a biomarker in preeclampsia?

Prokinetisin 1 preeklampsi belirteci olarak kullanılabilir mi?

Pages
1368–1372
Publication Date
2022-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

All tests were two-tailed, and p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract Can prokineticin 1 be used as a biomarker in preeclampsia?
📊
Key Findings & Data:Prokineticin 1 (PROK1) is reported to be the major subgroup affecting the female reproductive development.
💡
Conclusion & Impact:All tests were two-tailed, and p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:preeklampsi · prokinetisin 1 · belirteç

Abstract

Abstract Can prokineticin 1 be used as a biomarker in preeclampsia? Aim: Prokineticins are a group of peptides which play important roles in angiogenesis, hematopoiesis and reproduction. Prokineticin 1 (PROK1) is reported to be the major subgroup affecting the female reproductive development. PROK1 is secreted from the syncytiotrophoblasts and it prevents extravillous trophoblastic cell migration in the first trimester which predispose to the abnormal placentation and preeclampsia (PE). Hypoxia provokes the expression of PROK1 therefore its serum levels increase in pregnants with PE. The aim of the present study was to reveal the value of PROK1 as a marker of PE. Materials and Method: A total of 84 pregnant women were admitted to the study, and 43 of them were diagnosed with preeclampsia. 41 healthy pregnant women were included in the control group. The preeclampsia group was divided into two subgroups as mild PE (n=27) and severe PE (n=16). About 10 ml of venous blood was collected from each participant and dispensed into lithium heparin, and serum was obtained, which were stored at – 80 c until analyzed. Serum PROK1 measurements were performed by using an enzyme-linked immunosorbent assay (ELİSA). All tests were two-tailed, and p

Özet

Prokinetisin 1 preeklampsi belirteci olarak kullanılabilir mi? Amaç: Prokinetisinler, gastrointestinal sistemde görev aldığı saptanan bir grup peptidden oluşur ve 3 alt gruba ayrılır. Anjiogenezde, hematopoezde ve üremede önemli rolleri olduğu saptanmıştır. Anjiogenezde vasküler endotelyal büyüme faktörüne (VEGF) benzer rol aldığından dolayı EG-VEGF (endokrin gland kaynaklı vasküler endotelyal büyüme faktörü) olarak da adlandırılır. Bağışıklık sistemiyle de ilişkili olduğu gösterilen prokinetisinlerin kadın genitoüriner sistemini en çok etkileyen alt grubu prokinetisin 1’dir (PROK1). PROK1 sinsityotrofoblastlardan salınmakta olup plasentanın büyüme ve matürasyonu için hayati öneme sahiptir. PROK1, extravillöz trofoblastik hücre göçünü ilk trimesterde engeller. Hipoksi, PROK1’in ekspresyonunu uyararak preeklamptik gebelerde serum PROK1 düzeyini arttırır. Bu çalışma ile PROK 1 preeklampsi (PE) öngörüsünde bir belirteç olarak kullanabilir mi sorusuna cevap aramaktayız. Gereçler ve Yöntem: Çalışmaya Ümraniye Araştırma ve Eğitim Hastanesi Kadın Hastalıkları ve Doğum Kliniği'nde Ekim 2016-Eylül 2017 tarihleri arasında başvuran 84 gebe dahil edildi. PE tanısı alan 43 gebe vaka grubuna, 41 sağlıklı gebe kontrol grubuna dahil edildi. PE grubu; hafif PE (n=27) ve şiddetli PE (n=16) olmak üzere iki alt gruba ayrıldı. Bulgular: Gruplar arasında anne yaşı (yıl) ve başvuru sırasındaki gebelik yaşı açısından anlamlı bir fark saptanmadı. Doğum haftası, PE grubunda kontrol grubuna göre anlamlı olarak daha kısaydı (38.8 ± 1.43'e karşı 35.93 ± 3.5; p

🔖

Cite This Article

ULU, İ., KÖPÜK, Ş. Y., ÇEKMEZ, Y., KIRAN, G. (2022). Can prokineticin 1 be used as a biomarker in preeclampsia?. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, Cilt: 19 - Sayı: 3, 1368–1372. https://ajindex.com/articles/676478

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Li M, et al. Identification of two prokineticin cDNAs: recombinant pro- teins potently contract gastrointestinal smooth muscle. Mol Pharmacol 2001;59:692–8
  2. LeCouter J, Ferrara N. EG-VEGF and the concept of tissue-specific angio- genic growth factors. Semin Cell Dev Biol 2002;13:3–8
  3. LeCouter J, et al. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci U S A 2004;101:16813–8
  4. Ngan ES, et al. Prokineticin-1 (Prok-1) works coordinately with glial cell line-derived neurotrophic factor (GDNF) to mediate proliferation and differentiation of enteric neural crest cells. Biochim Biophys Acta 2008;1783:467–78
  5. Brouillet S, et al. EG-VEGF: a key endocrine factor in placental develop- ment. Trends Endocrinol Metab 2012;23:501–8
  6. Hoffmann P, Feige JJ, Alfaidy N. Placental expression of EG-VEGF and its receptors PKR1 (prokineticin receptor-1) and PKR2 throughout mouse gestation. Placenta 2007;28:1049–58
  7. LeCouter J, et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001;412:877–84
  8. Brouillet S, et al. Molecular characterization of EG-VEGF-mediated angiogenesis: differential effects on microvascular and macrovascular endothelial cells. Mol Biol Cell 2010;21:2832–43
  9. Hoffmann P, et al. Role of EG-VEGF in human placentation: physiological and pathological implications. J Cell Mol Med 2009;13:2224–35
  10. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785–99
  11. Brouillet S, et al. Revisiting the role of hCG: new regulation of the angiogenic factor EG-VEGF and its receptors. Cell Mol Life Sci 2012;69:1537–50
  12. Hoffmann P, Feige JJ, Alfaidy N. Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy. Endocrinology 2006;147:1675–84
  13. Sergent F, Hoffmann P, Brouillet S, Garnier V, Salomon A, Murthi P, Ben- harouga M, Feige JJ, Alfaidy N. Sustained EG-VEGF levels beyond the first-trimester of pregnancy display phenotypic and functional changes associated with the pathogenesis of pregnancy-induced hypertension. Hypertension 2016;68
  14. Petrik JJ, et al. Effects of rosiglitazone on ovarian function and fertility in animals with reduced fertility following fetal and neonatal exposure to nicotine. Endocrine 2009;36:281–90
  15. Ajonuma LC, et al. EG-VEGF concentrati